Group 1: Medline's IPO Details - Medline has priced its IPO at $29 per share, above the midpoint of the initial pricing range, raising $6.3 billion by issuing 216 million shares [3] - The company initially planned to issue 170 million shares, with the proceeds expected to be used for share buybacks from existing shareholders [3] - The fully diluted market capitalization of Medline is estimated at $38.7 billion, which is 4% higher than previous expectations [3] Group 2: Medline's Business Operations - Medline is a major distributor and manufacturer of medical surgical products, offering approximately 335,000 products across two main business segments: Medline brand products and supply chain solutions [4] - About one-third of Medline's branded products are produced in its 33 global manufacturing facilities, while the rest are sourced from over 500 suppliers [4] - The company operates a distribution network with 69 distribution centers and over 2,000 trucks, enabling it to serve approximately 95% of U.S. customers within a day [4] Group 3: Underwriters and Coordinators - Goldman Sachs, Morgan Stanley, Bank of America Securities, and JPMorgan Chase are serving as global coordinators and lead underwriters for the IPO [5] - A range of other banks, including Barclays, Citigroup, and Deutsche Bank Securities, are acting as book managers for the offering [5] Group 4: One Universe Acquisition SPAC - One Universe Acquisition, a SPAC led by Chinese executives, has filed for an IPO to raise up to $60 million by offering 6 million shares at $10 each [6] - The SPAC aims to acquire companies with strong management teams, mature products, and reliable revenue sources [7] - One Universe Acquisition plans to list on NASDAQ under the ticker symbol ONEU and was established in 2025 [7]

Core Viewpoint - Nasdaq is set to launch "around-the-clock trading" services starting in 2026 to meet the growing demand from investors for continuous trading in the U.S. stock market [3][4]. Group 1: Around-the-Clock Trading - Nasdaq plans to extend daily trading hours from 16 hours to 23 hours, operating five days a week, with a new schedule that includes a daytime session from 4:00 AM to 8:00 PM and a night session from 9:00 PM to 4:00 AM [5]. - The initiative aims to enhance the ability of investors, particularly those outside the U.S., to respond quickly to market dynamics occurring outside regular trading hours [6]. - Other exchanges, including the New York Stock Exchange and the Chicago Board Options Exchange, have announced similar plans for around-the-clock trading [4]. Group 2: Medline IPO - Medline, the largest IPO of the year, is set to debut on Nasdaq with an offering price of $29 per share for 216 million shares, aiming to raise approximately $6.26 billion, which values the company at around $39 billion [7]. - The company has reported revenues of $20.6 billion and a net profit of $977 million for the past nine months, showing an increase from $18.7 billion in revenue and $911 million in net profit in the same period last year [7]. - Major investors in Medline's IPO include Blackstone, Carlyle Group, and Hellman & Friedman, with cornerstone investors committing up to $2.35 billion [8].

Group 1: Nasdaq's All-Day Trading Initiative - Nasdaq has submitted a proposal to the SEC to launch "all-day trading" services starting in 2026, aiming to meet the growing demand for continuous trading from investors [1][2] - The plan includes extending daily trading hours from 16 to 23 hours, operating five days a week, with a new schedule that includes a one-hour maintenance window [3] - This initiative reflects a trend towards globalization in trading, with other exchanges like the New York Stock Exchange and Chicago Board Options Exchange also announcing similar plans [2][4] Group 2: Medline's IPO - Medline's IPO, set to take place on December 17, is expected to be the largest in the U.S. for the year, with a pricing of $29 per share for 216 million shares, aiming to raise approximately $6.26 billion [4][5] - The company, which produces medical supplies, has seen significant growth, reporting revenues of $20.6 billion and a net profit of $977 million for the past nine months [5][6] - Medline's IPO is notable as it ranks among the few U.S. IPOs in the last decade to raise over $5 billion, joining the ranks of companies like Uber and Rivian [6]

Group 1: Nasdaq's All-Day Trading Initiative - Nasdaq has submitted a proposal to the SEC to launch "all-day trading" services starting in 2026, aiming to meet the growing demand for continuous trading from investors [1][2] - The plan includes extending daily trading hours from 16 hours to 23 hours, operating five days a week, with a new structure of daytime and nighttime trading sessions [3] - The initiative reflects a trend towards globalization in trading, with Nasdaq's president emphasizing the increasing global nature of the U.S. market [2][4] Group 2: Medline's IPO - Medline, the largest IPO of the year, is set to debut on Nasdaq on December 17, with an offering price of $29 per share for 216 million shares, aiming to raise approximately $6.26 billion [4][6] - The company, founded in 1966, specializes in medical supplies and has reported revenues of $20.6 billion and a net profit of $977 million for the past nine months [5] - Medline's existing shareholders include major private equity firms, and the IPO has attracted cornerstone investors with commitments totaling up to $2.35 billion [5][6]

Core Viewpoint - Medline Inc. has successfully completed the largest IPO in the U.S. this year, raising $6.26 billion with a final pricing of $29 per share for 216 million shares, leading to a market valuation of approximately $39 billion [1][2]. Group 1: IPO Details - The IPO is set to officially launch on the Nasdaq under the ticker "MDLN" on December 17, 2025, after an increase in the offering size [1]. - Medline's IPO fundraising exceeds that of the largest global IPO this year, which was $5.26 billion by Chinese battery manufacturer CATL, and also surpasses the $1.75 billion raised by Venture Global in January [2]. - This transaction marks the largest majority stake IPO ever executed by a private equity-controlled company, surpassing the $5.1 billion IPO of Lineage Inc. last year [2]. Group 2: Company Background - Medline was founded in 1966 by Jon Mills and Jim Mills, with the Mills family remaining the largest individual shareholders post-IPO, holding 17.8% of the voting rights [4]. - The company produces and distributes medical supplies used by hospitals and physicians, offering approximately 335,000 surgical products and achieving next-day delivery to 95% of U.S. customers [4]. - As of September 27, the company reported revenues of $20.6 billion and a net profit of $977 million for the nine months, compared to $18.7 billion in revenue and $911 million in net profit during the same period last year [4]. Group 3: Shareholder Composition - Major shareholders include private equity giants Blackstone, Carlyle Group, and Hellman & Friedman, each holding 18% of the voting rights after the transaction [4]. - The Mills family and affiliates have expressed interest in purchasing up to $250 million worth of stock in the IPO [4]. Group 4: Market Context - Over the past decade, only five companies have raised more than $5 billion in IPOs in the U.S., with Medline's $6.26 billion placing it among them, alongside Uber, Lineage, Rivian Automotive, and Arm Holdings [3]. - The total IPO fundraising in the U.S. (excluding SPACs) has exceeded $46 billion this year, although it remains slightly below the pre-pandemic average of nearly $50 billion per year [3].

Core Viewpoint - Medline Inc. has announced the pricing of its upsized initial public offering (IPO) of 216,034,482 shares of Class A common stock at a price of $29.00 per share, with trading expected to begin on December 17, 2025, under the symbol "MDLN" [1]. Group 1: IPO Details - The underwriters have been granted a 30-day option to purchase an additional 32,405,172 shares of Class A common stock [1]. - Medline plans to use the proceeds from the issuance of 179,000,000 shares to repay outstanding indebtedness under its senior secured term loan facilities, with the remainder allocated for general corporate purposes and offering expenses [1]. - The offering is expected to close on December 18, 2025, subject to customary closing conditions [1]. Group 2: Underwriters and Managers - Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities, and J.P. Morgan are acting as global coordinators and lead bookrunning managers for the offering [2]. - A number of other financial institutions are involved as bookrunning managers and co-managers for the proposed offering [2]. Group 3: Company Overview - Medline is the largest provider of medical-surgical products and supply chain solutions, serving all points of care [5]. - The company has a broad product portfolio, resilient supply chain, and leading clinical solutions aimed at improving healthcare providers' clinical, financial, and operational outcomes [5]. - Medline is headquartered in Northfield, Illinois, employs over 43,000 people worldwide, and operates in more than 100 countries [5].

We are getting some news on the IPO front. Our Leslie Picker joins us now with the very latest. Hey Les. >> Hey Scott.Yeah, I wanted to give you an update on the Medline IPO. I am told that bankers, the sponsors, the company are currently huddled together discussing pricing options for this deal. I am told that they're considering and discussing potentially upsizing the offering.However, at this point in time, they are unlikely to price at the high end, that $30, uh, that high end of the range that they had ...

Private equity-owned medical supplies giant Medline is targeting an offering of up to $7 billion in an upsized share sale, the Financial Times reported on Tuesday, citing people briefed on the talks. ...

Company Overview - Medline is set to price its IPO today, potentially becoming the largest IPO since Rivian four years ago, with a valuation at the high end of its range reaching $55 billion, which is over $20 billion higher than the amount paid by its private equity sponsors in 2021 [1][3] - The company manufactures and distributes medical supply products, including masks, gowns, and lab kits [2][3] Business Performance - Medline has demonstrated a resilient business model, achieving net sales growth each year since its inception in the 1960s, with a compound annual growth rate (CAGR) of 18% [4][5] - The company is expected to benefit from secular trends such as an aging population and consolidation among healthcare providers [4] Growth Strategy - Medline's growth strategy includes acquiring several companies and continuing to pursue additional acquisitions [4] - The concentration within Medline's business and its customer base is viewed as both a growth opportunity and a risk factor [5] Financial Considerations - The company has significant debt due to its acquisition by a consortium of private equity firms, but plans to use part of the IPO proceeds to repay some of this debt [6] - Interest rates were lower at the time of the acquisition in 2021, which has impacted the company's public valuation strategy [6] Market Context - The IPO comes at a time when the healthcare sector is experiencing an upswing, contrasting with the struggles faced by AI-related companies, which have seen declines in their market performance [9]

Company Overview - Medline is a medical supply company that manufactures and distributes products such as masks, gowns, and lab kits [3] - The company was taken private in 2021 by a consortium of private equity firms, including Blackstone, Carlyle, and Hellman & Friedman, marking the largest leveraged buyout (LBO) post-financial crisis [3][4] IPO Details - The IPO is expected to price tonight and could be one of the largest debuts in the public markets this year, potentially valued at $55 billion, which is over $20 billion higher than the acquisition price by its sponsors [1][4] - The IPO guidance suggests pricing toward the high end of the range, indicating strong investor interest [2] Business Performance - Medline has demonstrated a resilient business model, with net sales growing each year since its inception in the 1960s at a compound annual growth rate (CAGR) of 18% [4] - The company is expected to benefit from secular tailwinds such as an aging population and the consolidation of healthcare providers [5] Growth Strategy - Medline's growth strategy includes acquiring several companies and continuing this trend to enhance its market position [5] - The concentration within Medline's business and its customer base is viewed as both a potential advantage and a risk factor [6] Market Context - The IPO is seen as a critical test for the IPO market, which has a healthy backlog of deals for 2026, and for the private equity industry, which has faced challenges in finding exits for portfolio companies [4]